Elicio Therapeutics, Inc. (ELTX)
| Market Cap | 180.42M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.90M |
| Shares Out | 13.88M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ELTX
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system - the lymph nodes. We believe this site-specific delivery of disease-specific antigens, a...
Financial Performance
Financial StatementsNews
This Week's Scheduled IPOs
With the start of a new week comes the excitement surrounding a new set of companies looking to make an impact through their public offerings. According to Benzinga Pro, these enticing companies are sch...
Elicio Therapeutics IPO Registration Document (S-1)
Elicio Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.